BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.73
−8.74%Sep 15, 2026, 12:00 UTC
Biodexa Pharmaceuticals PLC entered into a warrant exercise agreement with an existing accredited investor for the exercise of 2,204,218 outstanding warrants at $1.05 per ADS, raising approximately $2.3 million in gross proceeds.
Source:Sep 11, 2026, 20:30 UTC
Biodexa Pharmaceuticals PLC announced its unaudited interim results for the six months ended June 30, 2026.
Source:Aug 19, 2026, 12:30 UTC
Biodexa Pharmaceuticals announced that its Serenta registrational Phase 3 trial for eRapa in Familial Adenomatous Polyposis has recruited 87 of 168 planned subjects, exceeding the halfway point.
Source:Jul 29, 2026, 20:30 UTC
Biodexa Pharmaceuticals PLC shareholders passed all four resolutions at the general meeting held on July 29, 2026.
Source:Jul 29, 2026, 12:30 UTC
Biodexa Pharmaceuticals held its first round table meeting in Paris, France to expand support activities for Familial Adenomatous Polyposis patients and treatment centers.
Source:Jun 30, 2026, 12:00 UTC
Biodexa Pharmaceuticals priced a $3.5 million combined registered direct offering, concurrent private placement, and warrant inducement, including 282,952 ADSs at $2.85 per ADS.
Source: